Evaluating Mindfulness-Based Interventions With New Fibromyalgia Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04720053 |
Recruitment Status :
Recruiting
First Posted : January 22, 2021
Last Update Posted : January 23, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Fibromyalgia | Device: Wearable brain sensing wellness device headband system | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 40 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Feasibility Study Evaluating Mindfulness-Based Intervention Assessing- A Wearable Wellness Brain Sensing Device (Muse-S) in Newly Diagnosed Fibromyalgia Patients. |
Actual Study Start Date : | November 1, 2021 |
Estimated Primary Completion Date : | July 2023 |
Estimated Study Completion Date : | July 2023 |

Arm | Intervention/treatment |
---|---|
Experimental: Wearable brain sensing wellness device headband system
Subject diagnosed with fibromyalgia at Mayo Clinic GIM Fibromyalgia Clinic will receive a wearable brain sensing wellness device headband system, and will be given a demonstration of the mindfulness sessions, with detailed instructions on how to begin each session.
|
Device: Wearable brain sensing wellness device headband system
Brain sensing headband that measures brain activity by detecting electrical impulses created by the brain. |
- Change in wide pain index (WPI) [ Time Frame: Baseline, end of treatment day 90, and at the end of study day 180 ]Wide pain index (WPI) defined as a 4-quadrant plus axial pain, measuring widespread pain in 19 specific places on both sides of the body, above and below the waist
- Change in symptom severity score [ Time Frame: Baseline, end of treatment day 90, and at the end of study day 180 ]Measured on a 0-10 pain assessment scale. Participants rate their pain on a scale of 0 to 10. Zero means "no pain," and 10 means "the worst possible pain".

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- 18 years of age or older at time of consent.
- Diagnosed with Fibromyalgia.
- Not pregnant by subject self-report at time of consent.
- Have the ability to provide informed consent.
- Have the ability to complete all aspects of this trial.
- Have access to a iPhone, iPad, Android device.
- Has no contraindicating comorbid health condition as determined by the clinical investigators.
Exclusion Criteria:
- Used or been enrolled in any treatments for fibromyalgia, or pain within the past 30 days.
- Used an investigational drug within the past 30 days.
- Currently (within the past 3 weeks) been practicing mindfulness training on a weekly/regular basis.
- Currently (within the past 3 weeks) been undergoing an additional program (e.g. CAM) to improve quality of life.
- Currently (within 3 weeks) been enrolled in another clinical or research program (e.g. CAM) which intervenes on the patients' QOL, or stress.
- An unstable medical or mental health condition as determined by the physician investigator.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04720053
Contact: Jennifer Soderlind | (507) 284-4799 | GIMRESEARCHSTUDIES@Mayo.edu | |
Contact: Shawn Fokken | (507) 293-2740 | GIMRESEARCHSTUDIES@Mayo.edu |
United States, Minnesota | |
Mayo Clinic in Rochester | Recruiting |
Rochester, Minnesota, United States, 55905 | |
Contact: Jennifer Soderlind soderlind.jennifer@mayo.edu | |
Contact: Jennifer Hanson hanson.jennifer6@mayo.edu | |
Principal Investigator: Sanjeev Nanda |
Principal Investigator: | Sanjeev Nanda, MD | Mayo Clinic |
Responsible Party: | Sanjeev Nanda, Principal Investigator, Mayo Clinic |
ClinicalTrials.gov Identifier: | NCT04720053 |
Other Study ID Numbers: |
20-003020 |
First Posted: | January 22, 2021 Key Record Dates |
Last Update Posted: | January 23, 2023 |
Last Verified: | January 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Fibromyalgia Myofascial Pain Syndromes Muscular Diseases Musculoskeletal Diseases |
Rheumatic Diseases Neuromuscular Diseases Nervous System Diseases |